The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus-hepatitis B virus coinfection: a meta-analysisReportar como inadecuado




The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus-hepatitis B virus coinfection: a meta-analysis - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Virology Journal

, 9:186

First Online: 06 September 2012Received: 10 December 2011Accepted: 29 August 2012

Abstract

BackgroundClinical and laboratory studies have indicated that coinfection with hepatitis B virus HBV and hepatitis C virus HCV can suppress one another, eliciting a dominant disease phenotype. To assess whether HBV can influence the antiviral effect of treatment on HCV, we performed a meta-analysis to comparatively analyze the response to interferon plus ribavirin treatment in patients with HBV-HCV coinfection and HCV mono-infection.

MethodsPublished studies in the English-language medical literature that involved cohorts of HBV-HCV coinfection and HCV mono-infection were obtained by searching Medline, Cochrane and Embase databases. Studies that compared the efficacy of treatment with interferon plus ribavirin in HBV-HCV coinfection and HCV mono-infection were assessed. End-of-treatment virological response ETVR, sustained virological response SVR, HCV relapse rate, and alanine aminotransferase ALT normalization rate were compared between HBV-HCV coinfection and HCV mono-infection patients.

ResultsFive trials involving 705 patients were analyzed. At the end of follow-up serum ALT normalization rates in patients with HCV mono-infection were significantly higher than in patients with HBV-HCV coinfection odds ratio OR = 0.56, 95% confidence interval CI: 0.40–0.80, P = 0.001. The ETVR and SVR achieved in HBV-HCV coinfection patients were comparable to those in HCV mono-infection patients OR = 1.03, 95% CI: 0.37–2.82, P = 0.96 and OR = 0.87, 95% CI: 0.62–1.21, P = 0.38, respectively. The rate of relapse for HCV or HCV genotype 1 was not significantly different between HBV-HCV coinfection patients and HCV mono-infection patients OR = 1.55, 95% CI: 0.98–2.47, P = 0.06; HCV genotype 1: OR = 2.4, 95% CI: 1.17–4.91, P = 0.19.

ConclusionsTreatment with interferon and ribavirin achieves similar ETVR and SVR in HBV-HCV coinfection and HCV mono-infection. HBV-HCV coinfection patients had distinctively lower end of follow-up serum ALT normalization.

KeywordsCoinfection Hepatitis B Hepatitis C Interferon Ribavirin AbbreviationsHBVHepatitis B Virus

HCCHepatocellular Carcinoma

CHBChronic Hepatitis B

CHCChronic Hepatitis C

HBsAgHepatitis B Surface Antigen

ALTAlanine Aminotransferase

ETVREnd-of-Treatment Virological Response

SVRSustained Virological Response

HIVHuman Immunodeficiency Virus

RRRelative Risk

CIConfidence Interval

PEG-IFNPegylated-Interferon.

Electronic supplementary materialThe online version of this article doi:10.1186-1743-422X-9-186 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Autor: Jun-Ying Liu - Yun-Jian Sheng - Huai-Dong Hu - Qing Zhong - Jing Wang - Shi-Wen Tong - Zhi Zhou - Da-Zhi Zhang - Peng Hu

Fuente: https://link.springer.com/







Documentos relacionados